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Summary
Behavioural weight management interventions in research studies and clinical prac-
tice differ in length, advice, frequency of meetings, staff, and cost. Few real‐world
programmes have published patient outcomes and those that have used different
ways of reporting information, making it impossible to compare interventions and
develop the evidence base. To address this issue, we have developed a core outcome
set for behavioural weight management intervention programmes for adults with
overweight and obesity. Outcomes were identified via systematic review of the liter-
ature. A representative expert group was formed comprising people with experience
of adult weight management services. An online Delphi process was employed to
reach consensus as to which outcomes should be measured and reported and which
definitions/instruments should be utilised. The expert group identified eight core out-
comes and 12 core processes for reporting by weight management services. Eleven
outcomes and five processes were identified as optional. The most appropriate
definitions/instruments for measuring each outcome/process were also agreed. Our
core outcome set will ensure consistency of reporting. This will allow behavioural
weight management interventions to be compared, revealing which interventions
work best for which members of the population and helping inform development of
adult behavioural weight management interventions.
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1 | INTRODUCTION
Behavioural weight management interventions (BWMIs), known in
the United Kingdom (UK) as tier 2 services, are the first line treat-
ment for overweight and obesity1-4. International guidelines, includ-
ing those of The National Institute for Health and Care Excellence
(NICE)1, Scottish Intercollegiate Guidelines Network (SIGN)2, and
the American College of Cardiology/American Heart Association
Task Force on Practice Guidelines and The Obesity Society3, outline
the intervention components to be included in a behavioural weight
management programme for adults. These components, which
include calorie restriction, increased physical activity and behav-
ioural change support, have proven efficacy in randomised con-
trolled trials3. However, their implementation in practice is
inconsistent. Indeed, mapping exercises in Scotland4 and England5
revealed wide variation in adult weight management services with
regard to inclusion criteria, referral routes, delivery format, pro-
gramme length and cost, despite the single‐payer health care system.
Furthermore, few adult BWMIs have published outcome data and
where these data are published, results are often poor with low
levels of programme completion and “success,” with a lack of longer
term outcomes6,7.
When developing the guidance, “Weight management: lifestyle
services for overweight or obese adults”1 in 2014, NICE identified
a number of evidence gaps. These included reliance on studies with
short follow‐up, collection of data at limited time points, small sam-
ple sizes, demographic samples that limit the ability to generalise,
nonreporting of reasons for people dropping out and lack of evi-
dence regarding the effect of population characteristics, such as
age, gender, and socio‐economic status, on the effectiveness of a
service. NICE specifically mentioned “variable outcome definitions”
used in the clinical trials, which formed the supporting systematic
review and meta‐analysis, as a major barrier to developing
evidence‐based guidance. As a result, they were left with many evi-
dence gaps including “a lack of trials directly comparing lifestyle
weight management programmes in the UK” and “a general lack of
evidence on which specific components of a lifestyle weight man-
agement programme ensure effectiveness.” This lack of an evidence
base from both clinical trials and real‐world services means that it
is not possible to issue clear guidance as to which services are cost
effective for which population groups.
Public health bodies in the United Kingdom have made efforts to
try and address this issue; Public Health England (PHE)8 created a
standard evaluation framework (SEF) for weight management
programmes9. However, PHE was unable to analyse data from real
world interventions due to the heterogeneity of reporting, suggesting
further guidance is required. This heterogeneity can be exemplified by
reporting of weight loss, which included number of kilograms lost, per-
centage weight loss, average number of completers achieving 5%
weight loss, and body mass index (BMI)5. With regard to clinical trials,
evidence suggests similarly heterogeneous reporting of outcomes7.
It is acknowledged that the provision of treatments for obesity is
severely limited across the world,10-14 and large gaps in the evidence
of effectiveness may be contributing to this. An improved evidence
base would allow intervention programmes to be commissioned and
funded by health systems with the confidence of effectiveness. There
is an urgent need to gain consensus on standardised outcome
reporting to allow better comparison and meta‐analysis of interven-
tions to be performed across both real world and trial interventions.
Therefore, the specific aim of this study was to use Delphi methodol-
ogy to gain expert consensus opinion on the core outcomes that
should be reported from BWMIs in real‐world clinical practice as well
as within research studies and on the outcome definitions/outcome
measurement instruments that should be used in their evaluation.
Core outcome set (COS) development has an established methodol-
ogy,15 and COS represent the minimum that should be reported in
all clinical trials of a specific condition, while also being suitable for
observation research and audit; their use in clinical trials is supported
by the UK National Institute of Health Research (NIHR)16 as it allows
trial results to be easily compared and combined. However, the devel-
opment of a COS does not imply that research outcomes should be
restricted to only those included in the COS. The development of
these core outcome and definition/instrument sets for BWMIs will
ensure more consistency in the measurement of the effectiveness
of weight management services, leading to a better evidence base
from which to identify which services are effective across a range
of settings.
2 | METHODS
2.1 | Ethics
Ethical approval for this study was received from the University of
Glasgow College of Medical, Veterinary and Life Sciences Ethics
Committee.
The project has been registered with the COMET (Core Outcome
Measures in Effectiveness Trials) Initiative (http://www.comet‐initia-
tive.org/studies/details/1056), and a detailed methodology has been
reported previously17. In reporting the development of our COS, we
have adhered to the COS‐STAR (Core Outcome Set‐STAndards for
Reporting) Statement (Table S1)18.
2.2 | Identification of outcomes
In order to develop a COS, a comprehensive list of outcomes for
reporting from BWMIs was generated. These outcomes were identi-
fied following review of studies included in the systematic review,
“The clinical effectiveness of long‐term weight management schemes
for adults” by Hartmann‐Boyce et al7, conducted during the develop-
ment of NICE guidance1. This review was updated to cover the time
period 1 November 2012, until 30 September 2017, using the same
inclusion criteria (inclusion criteria and additional studies are outlined
in Section S1). Both primary and secondary outcomes from studies
were identified by two independent researchers and entered into a
spreadsheet. Additionally, the PHE SEF9, minimum dataset,19 and
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key performance indicators (KPI) document20 were reviewed, again by
two independent researchers, and any supplementary outcomes
added to the aforementioned spreadsheet. Of note, the PHE SEF9
was developed following focus group work with a wide range of stake-
holders, including weight management staff, primary care staff, aca-
demics, commissioners, and policy makers, and has been refined
over two versions from 2009 to 2018.
2.3 | Identification of outcome measurement
instruments/outcome definitions
Analyses of studies identified during the systematic review by
Hartmann‐Boyce7 and our updated search (Section S1) allowed instru-
ments and definitions for selected outcomes to be added to the data
extraction spreadsheet by two independent researchers. This list was
then examined by all study investigators and further suitable
instruments/definitions added.
2.4 | Participants
The core outcome and instrument set was developed by means of
consensus from an expert group, recruited as outlined previously17
and selected based on our sampling framework (Section S2) to ensure
a representative sample and a pragmatic and patient‐centred COS. All
experts recruited were from the United Kingdom.
For the stage 1 (outcome selection) Delphi process, agreement to
participate was obtained from 10 members of the public with
experience of NHS, local authority, or commercial weight management
programmes in the United Kingdom, 10 academics/policy
makers/commissioners working in weight management, 10 weight
management staff involved in delivering a lifestyle weight manage-
ment programme for adults (without significant policy involvement),
and 10 primary care staff with experience of referring patients to
weight management programmes (Table S2).
With regard to members of the public, in line with the sampling
framework, six of 10 had experience of commercial BWMIs (60%),
six of 10 were of working age (60%), and four of 10 were male
(40%) (Table S2). The 10 members of the public represented nine dif-
ferent UK counties (six Scottish counties and three English counties).
As per the sampling framework, nine of the 10 academics/policy
makers/commissioners were from England (90%), four of the 10 were
academics (40%), three of the 10 were policy makers (30%), and three
of the 10 were commissioners (30%) (Table S2).
Seven of the 10 primary care staff (70%) and eight of the 10 weight
management staff (80%) selected were from England (Table S2).
For the second Delphi process (stage 2, instrument/definition
selection), 20 academics/policy makers/commissioners and 20 weight
management staff were invited to participate and included those
who had successfully completed all three rounds of the stage 1 Del-
phi. The stage 2 Delphi involved reading papers, looking at metrics
and assessing validity of instruments/questionnaires. With such a
level of knowledge and expertise required, members of the public
and primary care staff were not involved in this stage of the Delphi
process.
Broadly in keeping with our sampling framework, 16 of the 20
stage 2 academics/policy makers/commissioners group members were
from England (80%), 11 of the 20 were academics (55%), four of the
20 were policy makers (20%), and five of the 20 were commissioners
(25%) (Table S3).
With regard to weight management staff, as per our sampling
framework, 14 of the 20 group members were from England (70%)
(Table S3).
The research team conducting the study consisted of a clinical
trialist/obesity physician, a health psychologist/trialist in weight man-
agement and behaviour change, a public health researcher/specialist
advisor to PHE Obesity Team, and a researcher in cardiometabolic
medicine.
2.5 | Delphi survey
Delphi methodology was used to gain consensus from the expert
group. Two separate Delphi processes (stage 1 and stage 2) were
conducted using an online questionnaire system (www.clinvivo.
com). Each Delphi process ran over three sequential rounds with
the same group of participants (Figure 1). For both the outcome
selection and outcome measurement/outcome definition selection
(stage 1 and stage 2) Delphi processes, those who completed a
questionnaire in round 1 were eligible to participate in round 2,
and those who completed round 2 were eligible to participate in
round 3. In short, in order for the expert group to reach consensus,
only those completing a given questionnaire were eligible to com-
plete the subsequent questionnaire.
The stage 1, outcome selection Delphi, asked each expert to score
the importance of an outcome measure for use in BWMI outcome
reporting. The scale ran from 1 to 9 with 1 to 3 indicating that the out-
come was unimportant, 4 to 6 indicating that it was neither unimpor-
tant nor important (“unsure”), and 7 to 9 indicating that it was
important. During rounds 1 and 2, participants were also given the
opportunity to suggest additional outcomes. All outcomes, excluding
any rated unimportant by consensus (see Section 2.6) and including
any appropriate new outcomes, were carried forward to the subse-
quent round (Figure 1).
During the stage 2, definition/instrument selection Delphi, experts
were asked to score the appropriateness of outcome definitions and
instruments for measurement of outcomes. Again, this was done
using a 1 to 9 scale with 1 to 3 indicating that the
definition/instrument was inappropriate, 4 to 6 indicating that it was
neither appropriate nor inappropriate (“unsure”), and 7 to 9 indicating
that it was appropriate. During rounds 1 and 2, participants were once
more given the chance to suggest additional instruments/definitions.
As for stage 1, all instruments/definitions, excluding any rated unim-
portant by consensus (see Section 2.6) and including any new
instruments/definitions, were carried forward to the subsequent
round (Figure 1).
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For both stage 1 and stage 2 of the Delphi process, participant
responses were summarised and fed back in subsequent rounds with
participants receiving their own score and the expert group mean
score for each outcome or instrument/definition.
Following round 3 of the stage 1 Delphi, consensus on the
outcome set size and importance of outcomes was used to
develop an outcome set. Similarly, following round 3 of the stage
2 Delphi process, a final instrument set matched to the COS was
formed based on the consensus. In areas where there was no
consensus, the study team adjudicated, taking account of free text
comments.
2.6 | Statistical analysis
As outlined in our published protocol17, the Research and Develop-
ment (RAND)/University of California Los Angeles (UCLA) appropri-
ateness method21 was used to assess disagreement and
importance/appropriateness (and thus define consensus). This
involved calculating the mean score, the median score, the inter‐
percentile range (IPR, 30th and 70th), and the inter‐percentile range
adjusted for symmetry (IPRAS), for each item being rated. For a given
item, disagreement was indicated when the ratio of IPR to IPRAS (the
disagreement index) was greater than 1.
Importance/appropriateness was assessed simply as whether the
mean and/or median rating fell between 1 and 3 (unimportant/inap-
propriate), 4 and 6 (unsure), or 7 and 9 (important/appropriate).
At the end of each Delphi round, the mean and median ratings
were determined for individual outcomes/instruments and the distri-
bution of ratings summarised (Figure 1). Free text comments were
analysed qualitatively, creating a narrative summary of responses
based on the nine domains used in the questionnaire.
3 | RESULTS
3.1 | Outcome selection
A list of 94 outcomes for reporting from BWMIs was generated from
our review of the literature and systematic review process.
The 94 outcomes were mapped across appropriate domains by
consensus of three members of the research team at a face to face
meeting. The domains followed section headings used in the PHE
SEF9 and followed the weight management intervention chronolog-
ical pathway (the order in which a BWMI would record outcome
data as individuals progressed through the programme). There were
nine domains in total (Demographics, Physical Measurements,
Physical Activity, Diet, Comorbidities, Lifestyle Behaviours, Psycho-
logical Factors, Programme Specific Outcomes, and Length of
Follow‐up).
FIGURE 1 Schematic outlining the two stage Delphi study. In order to develop a core outcome set and definition/instrument set, Delphi
methodology was used to gain consensus from expert groups. Two Delphis (stage 1 and stage 2) were carried out online over three rounds of
questionnaires. The stage 1 Delphi focused on development of a core outcome set. The stage 2 Delphi focused on corresponding definition/
instrument selection. PHE, Public Health England; SEF, standard evaluation framework; KPI, key performance indicator
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3.2 | Delphi survey—Stage 1/outcome selection
3.2.1 | Round 1
The final list of domains and outcomes was used to develop an online
outcome selection (stage 1) questionnaire. Within the questionnaire,
an explanation/definition of each outcome was provided using lay ter-
minology as identified by the research team and approved by Clinvivo
staff. With the exception of the outcomes in the Demographics,
Programme Specific Outcomes, and Length of Follow‐up domains, all
outcomes required measurement and reporting at both the first visit
to a BWMI (baseline) and at the end of the programme/at follow‐up.
This resulted in a 148‐item questionnaire with 75 outcomes for
reporting at baseline and 73 outcomes at the end of the intervention.
The stage 1, round 1, Delphi questionnaire can be seen, as it appeared
to study participants, in Section S3. Of the 40 invited participants, 38
completed responses were received for the stage 1, round 1 Delphi
questionnaire, representing a 95% response rate (100% of members
of the public, academics, policy makers, commissioners, and weight
management staff and 80% of primary care staff).
One hundred two of 148 outcomes were rated as important by the
expert group (median rating greater than or equal to 7) with no evi-
dence of disagreement between group members. The 102 outcomes
rated as important were carried forward to the round 2 Delphi ques-
tionnaire (Table S4).
The remaining 46 outcomes were rated as being either unimpor-
tant or unsure (neither important nor unimportant) by the expert
group (median rating less than or equal to 6.5, Table S4. For all but
one outcome (1 month follow‐up time point, disagreement index
greater than 1), expert group members were again in agreement (Table
S4). Outcomes rated as unimportant or unsure were not carried for-
ward to round 2 (Table S4).
During the round 1 questionnaire, 19 additional outcomes were
suggested by expert group members (Table S5 and Section S4). The
study team decided that four of the 19 suggested outcomes were
unique and valid and would therefore be carried forward to the round
2 Delphi (Table S5), giving a total of 109 outcomes to be rated in this
round (three of the four additional outcomes were to be rated for
reporting at both first visit and end of programme).
3.2.2 | Round 2
The stage 1 round 2 Delphi questionnaire can be seen, as it appeared
to study participants, in Section S5.
Thirty‐three of 38 completed questionnaires were received,
representing an 86.8% response rate (100% of academics, policy
makers, and commissioners; 90% of members of the public; and
62.5% of primary care staff).
Following analyses of round 2 questionnaires, 87 of 109 out-
comes were found to have been rated as important by the expert
group (median rating greater than or equal to 7). The remaining 22
outcomes were rated as unsure (median rating less than or equal
to 6.5). No outcomes were rated as being unimportant, and no dis-
agreement was evident between group members for any of the rat-
ings (Table S4). Participants' free text comments from round 2 can
be seen in Section S6. No additional outcomes were suggested dur-
ing this round.
In order to enable development of an outcome set of a
manageable/practical size, the study team decided that outcomes
would be split into three categories (core, optional, and for exclusion)
based on both their mean and median rating.
TABLE 1 Outcomes to be considered core for measuring and
reporting by behavioural weight management interventions (BWMIs)
Time Point Outcome
Mean
Panel
Rating
Median
Panel
Rating
At baseline Weight 8.7 9
At follow‐up Weight 8.6 9
At follow‐up Completion 8.5 9
At follow‐up Attendance 8.3 9
At baseline BMI 8.3 9
At follow‐up BMI 8.2 9
Follow‐up time
point
12 mo 8 9
At baseline Diabetes status 7.5 8
At follow‐up Participant satisfaction 7.5 8
Follow‐up time
point
24 mo 7.5 8
At follow‐up Cost effectiveness 7.3 8
At baseline Age 7.2 8
At follow‐up Diabetes Status 7.2 8
At baseline QoL score 7.2 8
At follow‐up QoL score 7.2 8
At follow‐up Reason for dropout 7.2 8
At follow‐up Adverse events/unintended
consequences
7.1 8
At follow‐up Referral to specialist services 7.1 8
At baseline Gendera 6.8 8
At baseline Deprivation categorya 6.7 7
At baseline Physical disabilitya 6.3 7
At baseline Learning disabilitya 6.2 7
At baseline Ethnicitya 6.1 7
At baseline Formally diagnosed with a
mental health conditionb
Note. Outcomes rated by the expert panel as being most important with a
mean rating greater than 7 and a median rating greater than or equal to 8
were designated as core for measurement and reporting by BWMIs.
Abbreviations: BMI, body mass index; QoL, quality of life.
aMean scores were not greater than 7 and/or median scores were not
greater than or equal to 8, but outcomes are considered protected
characteristics.
bNew outcome added to ensure a comprehensive core outcome set.
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The 14 outcomes rated as most important with a mean rating
greater than 7 and a median rating greater than or equal to 8 were
designated as core for measurement and reporting by BWMIs
(Table 1). Of these 14 outcomes, four were to be measured and
reported at both first visit and at the end of the programme. An addi-
tional five outcomes (gender, ethnicity, deprivation category, learning
disability, and physical disability) were then added to the core
category. While these additional outcomes were rated as being impor-
tant by the expert group, mean scores were not greater than 7 and/or
median scores were not greater than or equal to 8. However, these
outcomes are considered protected characteristics22 and therefore
should be reported in government‐funded projects. Finally, an entirely
new outcome, “formally diagnosed with a mental health condition,”
was added to the core category as it was felt that its inclusion was
TABLE 2 Outcomes to be considered optional for measuring and reporting by behavioural weight management interventions (BWMIs)
Time Point Outcome
Mean Panel
Rating
Median Panel
Rating
At follow‐up Depression 6.9 8
At follow‐up Repeat referrals 7.1 7
At baseline High blood pressure 7 7
At baseline Depression 6.9 7
At baseline High future risk of diabetes (impaired fasting glucose, impaired glucose tolerance,
raised HbA1c levels)
6.8 7
At baseline Overall measure of comorbidity 6.8 7
At baseline Binge eating disorder 6.8 7
At follow‐up Representativeness 6.8 7
At follow‐up Referral to linked services 6.8 7
Follow‐up time point 6 mo 6.8 7
At follow‐up High blood pressure 6.7 7
At baseline Mobility issues 6.7 7
At follow‐up Overall measure of comorbidity 6.6 7
At follow‐up Cardiovascular risk 6.6 7
At follow‐up Self confidence 6.6 7
At follow‐up Sources of referral 6.6 7
At follow‐up Prescription of anti‐obesity medication 6.6 7
Follow‐up time point 18 mo 6.6 7
At follow‐up High future risk of diabetes (impaired fasting glucose, impaired glucose tolerance,
raised HbA1c Levels)
6.5 7
At follow‐up Binge eating disorder 6.5 7
At baseline High cholesterol/lipids 6.5 7
At baseline Importance of weight loss 6.5 7
At baseline Disordered eating 6.5 7
At follow‐up Blood pressure 6.5 7
At follow‐up Self esteem 6.5 7
At follow‐up Reach 6.5 7
Follow‐up time point 3 mo 6.5 7
At baseline Cardiovascular riska 6.4 7
At baseline Self‐confidencea 6.4 7
At baseline Self‐esteema 6.4 7
At baseline Blood pressurea 6.2 7
Note. Outcomes rated by the expert panel as being reasonably important with a mean rating greater than or equal to 6.5 and less than or equal to 7.1, and a
median rating less than or equal to 8 were designated as being optional for measurement and reporting by BWMIs.
Abbreviation: HbA1c, haemoglobin A1c.
aMean scores less than 6.5 for the first visit/baseline time point but corresponding follow‐up time point scores meet rating criteria for the optional list.
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TABLE 3 Outcomes not recommended for measuring and reporting by behavioural weight management interventions (BWMIs)
Time Point Outcome Mean Panel Rating Median Panel Rating
At baseline Confidence in ability to lose weight 6.4 7
At follow‐up Confidence in ability to lose weight 6.4 7
At follow‐up Sedentary time 6.4 7
At follow‐up Importance of weight loss 6.4 7
At baseline Daily fruit and vegetable intake 6.3 7
At follow‐up Fitness 6.3 7
At follow‐up Mobility issues 6.3 7
At follow‐up Disordered eating 6.3 7
At follow‐up Anxiety 6.3 7
At baseline Anxiety 6.2 7
At follow‐up Waist circumference 6.2 7
At follow‐up Leisure time physical activity 6.2 7
At follow‐up Body image 6.2 7
At baseline Leisure time physical activity 6.1 7
At follow‐up Nonleisure time physical activity 6.1 7
At follow‐up Daily fruit and vegetable intake 6 7
At baseline Body image 6 7
At baseline Nonleisure time physical activity 6 7
At baseline Family history of obesity 6 7
At baseline Smoking status 6 7
At baseline Suicidal thoughts 6 7
At baseline Sedentary time 5.9 7
At baseline Fitness 5.9 7
At baseline Weight loss history 5.9 7
At baseline Daily alcohol consumption 5.9 7
At baseline Asthma 5.9 7
At baseline Other addictive behaviour 5.9 7
At follow‐up Fat mass/body composition 5.9 7
At follow‐up Daily calorie consumption 5.9 7
At follow‐up Daily alcohol consumption 5.8 7
At baseline Fat mass/body composition 5.8 7
At baseline Daily calorie consumption 5.8 7
At follow‐up Waist to hip ratio 5.6 7
At baseline Waist circumference 6.2 6
At follow‐up High cholesterol/lipids 6.1 6
At baseline Advised To lose weight prior to routine surgery 6 6
At baseline Osteoarthritis 5.9 6
At baseline NAFLD 5.9 6
At follow‐up Overall quality of sleep 5.9 6
At baseline Overall quality of sleep 5.8 6
At baseline Obstructive sleep apnoea 5.8 6
At baseline Chronic back pain 5.8 6
At baseline Other health conditions requiring a specialist diet 5.8 6
At follow‐up Suicidal thoughts 5.7 6
(Continues)
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necessary to ensure both a comprehensive COS and alignment with
PHE KPI20. Therefore, the core set included 20 outcomes for mea-
surement and reporting by BWMIs (Table 1).
Twenty‐two outcomes were rated as being reasonably important
with a mean rating greater than or equal to 6.5 and less than or
equal to 7.1, and a median rating less than or equal to 8. These out-
comes were designated as being optional for measurement and
reporting by BWMIs. Of these 22 outcomes, nine were to be mea-
sured and reported at both first visit and at the end of the pro-
gramme. Of note, for four of these nine (blood pressure,
cardiovascular risk, self‐esteem, and self‐confidence), the mean rat-
ing was slightly less than 6.5 for the first visit time point. However,
with the corresponding end of programme/follow‐up time point
meeting the rating criteria for the optional list, it was felt that these
four outcomes should be included in order to ensure the follow‐up
measurement was meaningful with a baseline value to compare it
to. As such, the optional set included 22 outcomes for measurement
and reporting by BWMIs (Table 2).
The 37 outcomes rated as being least important by the expert
panel (mean less than 6.5 and median less than or equal to 7) were
grouped together in the “for exclusion” category. These outcomes
would not be recommended for measurement and reporting by
BWMIs unless participants gave a convincing argument for their inclu-
sion during the round 3 Delphi (Table 3).
3.2.3 | Round 3
The stage 1 round 3 Delphi questionnaire can be seen, as it appeared
to participants, in Section S7.
Prior to commencing the questionnaire, it was explained to partic-
ipants that the results of the first 2 rounds of Delphi questionnaires
had allowed lists of outcomes, which would be considered core and
optional for reporting by BWMIs to be made. It was explained that a
list of outcomes to be excluded had also been drafted and that we
would not recommend these outcomes be measured by BWMIs. Par-
ticipants were informed that this would not mean that a weight man-
agement service could not measure these excluded outcomes should
they wish to, but that measuring and reporting the other outcomes
should be considered a higher priority.
Participants were asked to study the lists and indicate whether
they agreed with the findings of the expert panel. They were advised
that should they disagree with the findings, they would have the
opportunity to express their disagreement and make suggestions as
to any changes they felt should be made. It was made clear that if a
number of participants were to express similar opinions, the lists
would be altered appropriately.
The 33 expert group members who completed the round 2 ques-
tionnaire were invited to participate in the round 3 Delphi. All 33
members completed questionnaires, representing a 100% response
rate for round 3. With 33/40 participants completing all three rounds
of the stage 1 Delphi process, the overall response rate for stage 1
was 82.5% (100% of academics, policy makers, and commissioners;
90% of weight management staff and members of the public; and
50% of primary care staff).
Following our analyses of the completed round 3 questionnaires,
25 of 33 participants (75.8%) indicated that they were in agreement
with the core and optional outcome sets. Comments from the eight
participants who were not in agreement are included within Section
S8. Having given these comments due consideration, the study team
were of the opinion that no changes were required to the core or
optional outcome sets (Tables 1 and 2) prior to the stage 2 (instrument
selection) Delphi process.
As outlined in Table 1, the final list of core outcomes included
“weight” (at baseline and follow‐up), “completion” (at follow‐up),
“attendance” (at follow‐up), ”BMI” (at baseline and follow‐up), “diabe-
tes status” (at baseline and follow‐up), “participant satisfaction” (at
TABLE 3 (Continued)
Time Point Outcome Mean Panel Rating Median Panel Rating
At follow‐up Obstructive sleep apnoea 5.7 6
At follow‐up Other addictive behaviour 5.6 6
At follow‐up Chronic back pain 5.6 6
At baseline Chronic kidney disease 5.6 6
At baseline Polycystic ovary syndrome (women only) 5.6 6
At baseline Autism 5.6 6
At baseline Personality disorders 5.6 6
At follow‐up Daily free sugar intake 5.6 6
At follow‐up Self‐reported reduction in clothes size 5.5 6
At follow‐up Neck circumference 4.9 5
At baseline Neck circumference 4.7 5
Note. Outcomes rated by the expert panel as being least important with a mean rating less than 6.5 and a median rating less than or equal to 7 were des-
ignated as being “for exclusion” and would therefore not be recommended for measurement and reporting by BWMIs, unless participants gave a convincing
argument for their recommendation during the round 3 Delphi.
Abbreviation: NAFLD, nonalcoholic fatty liver disease.
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TABLE 4 Stage 2 (instrument selection), round 1 Delphi results
Outcome
Set Outcome
Stage 2, Round 1 Questionnaire
Item and Brief Description Importance
Mean
Panel
Rating
Median
Panel
Rating
Disagreement
Index
(IPR:IPRAS) Report
Retain for
Stage 2,
Round 2
Delphi Discard
Core 3. Age 3.1. Mean age in years Important 7.3 8 0.16 ✓
3.2. % in age bands Important 7 7 0.16 ✓
Core 4. Weight 4.1. Mean weight in kg Important 8 9 0.13 ✓
4.2. Mean weight change in kg Important 7.8 9 0.29 ✓
4.3. Mean % weight change Important 8.1 9 0.13 ✓
4.4. % achieving ≥3% weight loss Important 6.5 7 0.65 ✓
4.5. % achieving ≥5% weight loss Important 7.6 8 0.29 ✓
4.6. % achieving ≥10% weight loss Important 7.5 8 0.29 ✓
4.7. % achieving ≥3 kg weight loss Unsure 5.3 5 0.85 ✓
4.8. % achieving ≥5 kg weight loss Unsure 5.7 5 1.04 ✓
4.9. % achieving ≥10 kg weight loss Unsure 5.8 5 1.04 ✓
Core 5. BMI 5.1. Mean BMI Important 7.8 8 0.29 ✓
5.2. % in BMI categories Important 7.6 8 0.29 ✓
5.3. Mean change in BMI Important 7.2 8 0.29 ✓
5.4. % achieving BMI <25 Unsure 5.2 6 0.85 ✓
5.5. % achieving BMI <30 Unsure 5.6 6 0.52 ✓
Core 6. Diabetes status 6.1. % with T1DM Unsure 5.8 5 0.52 ✓
6.2. % with T2DM Important 7.2 7 0.49 ✓
6.3. Mean HbA1c of those with T2DM Unsure 6.2 6 0.65 ✓
6.4. % of those with T2DM on insulin Unsure 5.9 6 0.65 ✓
6.5. Mean number of diabetes medications per
participant with T2DM
Unsure 5.5 6 0.97 ✓
6.6. Mean change in HbA1c of those with
T2DM
Important 6 7 0.52 ✓
6.7. Mean change in % of those with T2DM on
insulin
Unsure 5.5 6 0.52 ✓
6.8. Mean change in number of diabetes
medications per participant with T2DM
Unsure 5.5 6 0.52 ✓
Core 7. QoL score 7.1. Mean EQ‐5D‐5L scores (baseline) Important 6.7 7 0.65 ✓
7.2. Mean SF12 score (baseline) Unsure 5.8 6 0.52 ✓
7.3. Mean SF36 scores (baseline) Unsure 5.2 6 0.52 ✓
7.4. Mean IWQOL‐Lite score (baseline) Unsure 5.7 6 0.52 ✓
7.5. Mean OWLQOL scores (baseline) Unsure 5.4 5 0.52 ✓
7.6. Mean EQ‐5D‐5L scores (follow‐up) Important 6.6 7 0.65 ✓
7.7. Mean SF12 score (follow‐up) Unsure 5.8 6 0.52 ✓
7.8. Mean SF36 scores (follow‐up) Unsure 5.3 6 0.52 ✓
7.9. Mean IWQOL‐Lite score (follow‐up) Unsure 5.7 6 0.52 ✓
7.10. Mean OWLQOL scores (follow‐up) Unsure 5.5 5 0.52 ✓
Core 8. Learning disability
QoL score
8.1. Mean PWI‐ID score(s)
8.2. Mean score using another suitable
instrument
Unsure
Unsure
5.3
4.8
5
5
0.52
0.85
✓ ✓
Core 9. Adverse events/
unintended
consequences
9.1. Number experiencing a worsening of pre‐
existing medical condition
9.2. Number suffering severe hypoglycaemia
Important
Unsure
6
5.5
7
6
0.52
0.97
✓
✓
(Continues)
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TABLE 4 (Continued)
Outcome
Set Outcome
Stage 2, Round 1 Questionnaire
Item and Brief Description Importance
Mean
Panel
Rating
Median
Panel
Rating
Disagreement
Index
(IPR:IPRAS) Report
Retain for
Stage 2,
Round 2
Delphi Discard
(merge
with
9.1)
9.3. Number sustaining injury during physical
activity session
Important 6.2 7 0.52 ✓
9.4. Number experiencing other side effects Unsure 5.3 6 0.97 ✓
Core 10. Repeat referrals 10.1. % previously referred to service Important 6.3 7 0.65 ✓
10.2. % previously referred and attended ≥1
session
Important 6.3 7 0.52 ✓
Core 11. Attendance 11.1. Mean % core sessions attended Important 7.9 8 0.13 ✓
11.2. % attending 100% core sessions Unsure 6.3 6 0.22 ✓
11.3. % attending ≥80% core sessions Important 6.8 7 0.37 ✓
11.4. % attending ≥70% core sessions Important 6.5 7 0.37 ✓
11.5. % attending ≥50% core sessions Unsure 5.8 6 0.32 ✓
Core 12. Completion 12.1. % attended 100% core sessions Important 6.9 7 0.49 ✓
12.2. % attended 80% core sessions Important 6.8 7 0.49 ✓
12.3. % attended 70% core sessions Important 6.3 7 0.65 ✓
12.4. % attended 50% core sessions Unsure 5.6 6 0.32 ✓
Core 13. Reason for
dropout
13.1. % dropped out due to dissatisfaction with
intervention (unrelated to weight loss)
Important 6.7 7 0.37 ✓
13.2. % dropped out due to poor weight loss Important 6.8 7 0.37 ✓
13.3. % dropped out due to illness/
hospitalisation
Important 6.8 7 0.16 ✓
13.4. % dropped out due to pregnancy Important 6.5 7 0.37 ✓
13.5. % dropped out for social reason Important 6.3 7 0.22 ✓
13.6. % dropped out due to moving from the
locale
Important 6.4 7 0.22 ✓
13.7. % dropped out for another reason Important 6.2 7 0.52 ✓
Core 14. Participant
satisfaction
14.1. Mean adapted OEQ score
14.2 Mean NHS FFT score
Important
Important
6.4
6.3
7
7
0.37
0.65
✓
✓
Core 15. Cost
effectiveness
15.1. PHE Weight Management Economic
Assessment Tool
Important 6 7 0.52 ✓
15.2. Cost/kg based on mean weight loss Unsure 5.6 6 0.52 ✓
15.3. Cost/“success” (5% weight loss) Important 6 7 0.52 ✓
15.4. Cost/“success” (5 kg weight loss) Unsure 4.5 5 0.52 ✓
15.5. Cost/“success” (3% weight loss) Unsure 5.5 5 0.52 ✓
15.6. Cost/kg based on any change in weight
data
Unsure 4.8 5 0.97 ✓
Core 16. Presentation of
results
16.1. Report outcomes for all attending ≥1
active weight loss session
Unsure 5.9 6 0.52 ✓
16.2. Report outcomes for all attending >1
active weight loss session(s)/with weight
loss data
Important 6.4 7 0.37 ✓
16.3. Report outcomes for all completing
programme
Important 7.3 8 0.29 ✓
(Continues)
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TABLE 4 (Continued)
Outcome
Set Outcome
Stage 2, Round 1 Questionnaire
Item and Brief Description Importance
Mean
Panel
Rating
Median
Panel
Rating
Disagreement
Index
(IPR:IPRAS) Report
Retain for
Stage 2,
Round 2
Delphi Discard
17. High blood
pressure
17.1. % with high blood pressure based on
patient report/medication/case notes
17.2. % with high blood pressure based on
blood pressure readings
Important 6.2 7 0.65 ✓
17.3. Mean number blood pressure medications
per participant with high blood pressure
Unsure 5.7 6 0.52 ✓
17.4. Change in mean blood pressure Important 6.4 7 0.37 ✓
17.5. Change in mean number blood pressure
medications per participant with high blood
pressure
Unsure 5.6 6 0.52 ✓
Optional 18. Blood pressure 18.1. Mean systolic and diastolic blood pressure Important 6.4 7 0.65 ✓
18.2. % with blood pressure > 140/80 mmHg Unsure 5.9 6 0.52 ✓
18.3. % on blood pressure medication based on
self‐report/case records
Unsure 5.5 5 0.97 ✓
18.4. Change in mean systolic and diastolic
blood pressure
Unsure 6.3 6 0.65 ✓
18.5. Change in % with blood pressure > 140/
80 mmHg
Unsure 5.8 6 0.52 ✓
18.6. Change in % on blood pressure medication
based on self‐report/case records
Unsure 5.6 5 1.04 ✓
Optional 19. CV risk 19.1. % with previous CVD Important 6.6 7 0.22 ✓
19.2. % with high CVD risk Unsure 6.1 6 0.52 ✓
19.3. % with high CV risk score (baseline) Unsure 5.9 6 0.52 ✓
19.4. Mean CV risk score Unsure 5.3 6 0.97 ✓
19.5. % on CV medications Unsure 5.5 6 0.52 ✓
19.6. Mean number of CV medications per
participant on CV medication(s)
Unsure 4.8 5 0.85 ✓
19.7. % with high CV risk score (follow‐up) Unsure 5.6 6 0.52 ✓
19.8. Change in mean CV risk score Unsure 5.6 6 0.52 ✓
19.9. Change in % on CV medications
19.10. Change in mean number of CV
medications per participant on CV
medication(s)
Unsure
Unsure
4.9
4.8
5
5
0.85
0.97
✓
✓
Optional 20. High cholesterol/
lipids
20.1. % with high cholesterol/lipids based on
self‐report/case records (baseline)
Unsure 5.8 6 0.52 ✓
20.2. % on statin/lipid lowering medication
based on self‐report/case records (baseline)
Unsure 5.5 5 0.97 ✓
20.3. Mean total cholesterol/HDL/triglycerides
(baseline)
Unsure 5.6 6 0.52 ✓
20.4. % with high cholesterol/lipids based on
self‐report/case records (follow‐up)
Unsure 5.5 5 0.32 ✓
20.5. % on statin/lipid lowering medication
based on self‐report/case records (follow‐up)
Unsure 5.3 5 0.97 ✓
20.6. Mean total cholesterol/HDL/triglycerides
(follow‐up)
Unsure 5.4 6 0.97 ✓
Optional 21. High future risk
of diabetes
21.1. % with medical record of HDR (baseline) Unsure 6 6 0.52 ✓
21.2. % with HDR determined by OGTT
(baseline)
Unsure 4.8 5 0.85 ✓
(Continues)
MACKENZIE ET AL. 11 of 25
Optional Important 6.7 7 0.37 ✓
TABLE 4 (Continued)
Outcome
Set Outcome
Stage 2, Round 1 Questionnaire
Item and Brief Description Importance
Mean
Panel
Rating
Median
Panel
Rating
Disagreement
Index
(IPR:IPRAS) Report
Retain for
Stage 2,
Round 2
Delphi Discard
21.3. % with HDR determined by HbA1c
(baseline)
Unsure 5.9 6 0.52 ✓
21.4. % with medical record of HDR (follow‐up) Unsure 5.7 6 0.52 ✓
21.5. % with HDR determined by OGTT
(follow‐up)
Unsure 4.8 5 0.85 ✓
21.6. % of those with HDR at baseline who still
have HDR at follow‐up as determined by
OGTT
Unsure 4.7 4 0.85 ✓
21.7. % with HDR determined by HbA1c
(follow‐up)
Unsure 5.9 6 0.52 ✓
21.8. % of those with HDR at baseline who still
have HDR at follow‐up as determined by
HbA1c
Unsure 5.6 6 0.97 ✓
Optional 22. Overall Measure
of comorbidity
22.1. mean CCI score (baseline) Unsure 5 5 0.85 ✓
22.2. Mean EOSS score (baseline) Unsure 5.5 5 0.97 ✓
22.3. Mean Chronic Disease Score (baseline) Unsure 5 5 0.85 ✓
22.4. Mean number dispensed medications per
participant (baseline)
Unsure 5.3 5 0.52 ✓
22.5. Mean CCI score (follow‐up) Unsure 5 5 0.97 ✓
22.6. Mean EOSS score (follow‐up) Unsure 5.3 5 0.97 ✓
22.7. Mean Chronic Disease Score (follow‐up) Unsure 5 5 0.97 ✓
22.8. Mean number dispensed medications per
participant (follow‐up)
Unsure 5.2 6 0.97 ✓
Optional 23. Depression 23.1. % with depression based on self‐report/
medication/case notes (baseline)
Important 6.2 7 0.65 ✓
23.2. % on medication for depression (baseline) Important 5.9 7 0.52 ✓
23.3. Mean HADS score (baseline) Unsure 5.7 6 0.52 ✓
23.4. Mean PHQ9 score (baseline) Unsure 5.9 6 0.52 ✓
23.5. Mean Beck Depression Inventory score
(baseline)
Unsure 5.5 6 0.52 ✓
23.6. % on medication for depression (follow‐
up)
Unsure 5.7 6 0.97 ✓
23.7. % of those identified as having depression
at baseline on medication for depression
(follow‐up)
Unsure 5.6 6 0.52 ✓
23.8. mean HADS score (follow‐up) Unsure 5.6 6 0.52 ✓
23.9. Mean PHQ9 score (follow‐up)
23.10. mean Beck Depression Inventory score
(follow‐up)
Unsure
Unsure
5.8
5.3
6
6
0.52
0.32
✓
✓
Optional 24. Self‐confidence
and self‐esteem
24.1. Mean Tennesse Self‐concept Scale score
(baseline)
Unsure 4.4 5 0.52 ✓
24.2. Mean Rosenberg Self‐esteem Scale score
(baseline)
Unsure 5.3 5 0.97 ✓
24.3. Mean General Well‐being Schedule score
(baseline)
Unsure 5.1 5 0.85 ✓
24.4. Mean ICECAP‐A score (baseline) Unsure 4.9 5 0.85 ✓
24.5. Mean WEMWBS score (baseline) Unsure 5.8 6 0.52 ✓
(Continues)
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TABLE 4 (Continued)
Outcome
Set Outcome
Stage 2, Round 1 Questionnaire
Item and Brief Description Importance
Mean
Panel
Rating
Median
Panel
Rating
Disagreement
Index
(IPR:IPRAS) Report
Retain for
Stage 2,
Round 2
Delphi Discard
24.6. Mean Tennesse Self‐concept Scale score
(follow‐up)
24.7. Mean Rosenberg Self‐esteem Scale score
(follow‐up)
Unsure 5.3 5 0.97 ✓
24.8. Mean General Well‐being Schedule score
(follow‐up)
Unsure 5 5 0.85 ✓
24.9. Mean ICECAP‐A score (follow‐up)
24.10. mean WEMWBS score (follow‐up)
Unsure
Unsure
4.8
5.7
5
6
0.85
0.97 ✓
✓
Optional 25. Importance of
weight loss
25.1. Mean Dieting Readiness Scale score(s)
(baseline)
Unsure 5.4 5 0.97 ✓
25.2. Mean DIET score(s) (baseline) Unsure 5 5 0.85 ✓
25.3. Mean Self‐Efficacy for Eating Behaviours
Scale score(s) (baseline)
Unsure 5.1 5 0.97 ✓
25.4. Mean Dieting Readiness Scale score(s)
(follow‐up)
Unsure 5.3 5 0.97 ✓
25.5. Mean DIET score(s) (follow‐up) Unsure 4.9 5 0.97 ✓
25.6. Mean Self‐Efficacy for Eating Behaviours
Scale score(s) (follow‐up)
Unsure 5 5 0.97 ✓
Optional 26. Disordered
eating
26.1. % with disordered eating (defined as per
service) (baseline)
Important 6 7 0.52 ✓
26.2. Mean TEFQ score (baseline) Unsure 4.8 5 0.85 ✓
26.3. Mean EDEQ score (baseline) Unsure 5 5 0.85 ✓
26.4. Mean BES score (baseline) Unsure 5.2 5 0.97 ✓
26.5. Mean QEWP (baseline) Unsure 4.5 5 0.97 ✓
26.6. % with disordered eating (defined as per
service) (follow‐up)
Unsure 5.8 6 0.97 ✓
26.7. Mean TEFQ score (follow‐up) Unsure 4.8 5 0.85 ✓
26.8. Mean EDEQ score (follow‐up) Unsure 4.8 5 0.97 ✓
26.9. Mean BES score (follow‐up)
26.10. mean QEWP (follow‐up)
Unsure
Unsure
5.2
4.5
5
5
0.97
0.97
✓
✓
Optional 27. Reach 27.1. Age < 30 Unsure 5.6 6 0.52 ✓
27.2. Male Important 7.1 7 0.16 ✓
27.3. People with T2DM Important 7.2 7 0.16 ✓
27.4. Other subgroups Unsure 5.7 6 0.52 ✓
Optional 28.
Representativeness
28.1. Based on age Important 6.1 7 0.52 ✓
28.2. Based on sex Important 6.6 7 0.22 ✓
28.3. Based on BMI Important 6.7 7 0.37 ✓
28.4. Based on deprivation category Important 6.9 7 0.16 ✓
28.5. Based on ethnicity Important 6.6 7 0.37 ✓
28.6. Based on diabetes status Important 6.5 7 0.22 ✓
28.7. Based on other criteria Unsure 4.9 5 0.32 ✓
Optional 29. Prescription of
anti‐obesity
medication
29.1. % on any anti‐obesity medication
(baseline)
Important 6.5 7 0.00 ✓
29.2. % on specific anti‐obesity medications
(baseline)
Unsure 5.7 6 0.52 ✓
(Continues)
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Unsure 4.2 4 0.52 ✓
follow‐up), “cost effectiveness” (at follow‐up), ”age” (at baseline),
”Quality of Life (QoL) score” (at baseline and follow‐up), ”reason for
dropout” (at follow‐up), “adverse events/unintended consequences”
(at follow‐up), “referral to specialist services” (at follow‐up), “12” and
“24 months” follow‐up time points, and “gender,” “deprivation cate-
gory,” “physical disability,” “learning disability,” “ethnicity,” and “for-
mally diagnosed with a mental health condition” (all at baseline).
The final list of optional outcomes included “depression” (at base-
line and follow‐up), “repeat referrals” (at follow‐up), “high blood pres-
sure” (at baseline and follow‐up), “high future risk of diabetes” (at
baseline and follow‐up), “overall measure of comorbidity” (at baseline
and follow‐up), “binge eating disorder” (at baseline and follow‐up),
“representativeness” (at follow‐up), “referral to linked services” (at
follow‐up), “mobility issues” (at baseline), “cardiovascular risk” (at base-
line and follow‐up), “self‐confidence” (at baseline and follow‐up),
“sources of referral” (at follow‐up), “prescription of anti‐obesity medi-
cation” (at follow‐up), “high cholesterol/lipids” (at baseline), “impor-
tance of weight loss” (at baseline), “disordered eating” (at baseline),
“blood pressure” (at baseline and follow‐up), “self‐esteem” (at baseline
and follow‐up), “reach” (at follow‐up), and “6,”“18,” and “3 months”
follow‐up time points (Table 2).
With regard to outcomes for exclusion, 22 of 33 participants
(66.7%) indicated that they were in agreement. Comments from the
11 participants who were not in agreement are included within Sec-
tion S8. Again, following due consideration, the study team decided
that no excluded outcomes should be retained/added to the optional
outcome list prior to the stage 2 Delphi. The final list of outcomes
for exclusion following the stage 1 Delphi process was, therefore, as
outlined in Table 3.
3.3 | Outcome measurement instrument selection
By reviewing the trials identified by Hartman Boyce et al7 and our
update, definitions and instruments that could be used for
measurement of the core and optional outcomes selected during the
stage 1 Delphi process were listed (Table S6). Further, suitable defini-
tions and instruments for these outcomes were added based on the
study team's knowledge (Table S6).
For simplification, outcomes for which the definition or instrument
was well established or where only a single possible option was avail-
able were not included in the stage 2 process, while some outcomes
within the optional outcomes set were combined; “binge eating disor-
der” was combined with “disordered eating,” and, although slightly dif-
ferent concepts, “self‐esteem” and “self‐confidence” were combined.
Furthermore, an outcome relating to the presentation of results was
added to the core set for inclusion in the stage 2 Delphi. Due to having
specific instruments for their measurement, “learning disability QoL
score” and “physical disability QoL score” outcomes were also
included in the core set. In addition, as it had been borderline for inclu-
sion based on rank, required only a yes/no answer with no patient
burden and was specifically mentioned in NICE guidance1 as a ques-
tion for future research, the “repeat referrals” outcome (mean rating
of 7.1 and median rating of 7) was moved from the optional to the
core outcomes list (Table S6).
3.4 | Delphi survey—Stage 2/outcome measurement
instrument selection
3.4.1 | Round 1
The stage 2 round 1 Delphi questionnaire can be seen, as it appeared
to study participants, in Section S9. Documents 1 to 8 referred to
within the questionnaire were provided in parallel and included full
descriptions of all instruments and, where possible, peer‐reviewed
publications regarding their validity23-26.
Thirty‐three of 40 completed questionnaires were received,
representing an 82.5% response rate (85% ofweight management staff,
82% of academics, 80% of commissioners, and 75% of policy makers).
TABLE 4 (Continued)
Outcome
Set Outcome
Stage 2, Round 1 Questionnaire
Item and Brief Description Importance
Mean
Panel
Rating
Median
Panel
Rating
Disagreement
Index
(IPR:IPRAS) Report
Retain for
Stage 2,
Round 2
Delphi Discard
29.3. % on anti‐obesity medication (follow‐up) Important 6.2 7 0.22 ✓
29.4. % on specific anti‐obesity medications
(follow‐up)
Unsure 5.6 6 0.52 ✓
Note. Fifty‐six of 163 definitions/instruments were rated as appropriate by the expert group (median rating greater than or equal to 7) with no disagree-
ment between experts. One hundred seven definitions/instruments were rated as unsure (median rating less than or equal to 6.5). The expert group was in
agreement (disagreement index less than 1.0) for 104 of these 107 items.
Abbreviations: BES, Binge Eating Scale; BMI, body mass index; CCI, Charlson Comorbidity Index; CV, cardiovascular; CVD, cardiovascular disease; DIET,
Dieter's Inventory of Eating Temptations; EDEQ, Eating Disorder Examination Questionnaire; EOSS, Edmonton Obesity Staging System; EQ‐5D‐5L,
EuroQol 5‐level EQ‐5D version; FFT, Friends and Family Test; HADS, Hospital Anxiety and Depression Scale; HbA1c, haemoglobin A1c; HDL, high‐density
lipoprotein; HDR, high diabetes risk; ICECAP‐A, ICEpop CAPability measure for Adults; IPR, inter‐percentile range;IPRAS, inter‐percentile range adjusted
for symmetry; IWQOL‐Lite, 31‐Item Impact of Weight on Quality of Life; NHS, National Health Service; OEQ, Outcomes and Experiences Questionnaire;
OGTT, oral glucose tolerance test; OWLQOL, Obesity and Weight‐Loss Quality of Life; PHE, Public Health England; PHQ‐9, Patient Health Questionnaire‐
9; PWI‐ID, Personal Wellbeing Index–Intellectual Disability; QEWP, Questionnaire on Eating and Weight PatternsQoL, quality of life; SF12, 12‐Item Short
Form Health Survey; SF36, 36‐Item Short Form Health Survey; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TFEQ, Three Factor Eating
Questionnaire; WEMWBS, Warwick‐Edinburgh Mental Wellbeing Scale.
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Following analyses of completed questionnaires, 56 of 163
definitions/instruments were found to have been deemed appropriate
by the expert group (median rating greater than or equal to 7) with no
evidence of disagreement between expert panel members (Table 4).
The remaining 107 definitions/instruments were rated as unsure (nei-
ther appropriate nor inappropriate) by the expert group (median rating
less than or equal to 6.5). The expert group were in agreement (dis-
agreement index less than 1.0) for 104 of these 107 items (Table 4).
For all but eight outcomes, round 1 scores allowed discrimination
between the definition/instrument options provided. In the majority
of instances, options were selected for reporting if they were rated
as important (median score greater than or equal to 7). For outcomes
where none of the definition/instrument options were rated as impor-
tant (learning disability QoL score, high cholesterol/lipids, high future
risk of diabetes, and self‐confidence and self‐esteem), the highest
scoring of the options deemed unsure were selected (Table 4). In cases
where one of many definition/instrument options for an outcome
received a much higher rating than the others, this option was
selected for reporting and the lower scoring options were discarded
despite some being rated as important (median greater than or equal
to 7). An example of this can be seen for the “attendance” outcome
where item 11.1, “mean % of core/mandatory sessions attended by
participants“ (median value of 8 and mean value of 7.9) was selected
for reporting and items 11.3, “% of participants attending greater than
or equal to 80% of core/mandatory sessions,” and 11.4, “% of partici-
pants attending greater than or equal to 70% of core/mandatory ses-
sions,” (median values of 7 and mean values of 6.8 and 6.5,
respectively) were discarded. Conversely, for the “representativeness”
outcome, item 28.7, “based on other criteria” was included for
reporting despite being rated as unsure (median value of 5). This was
because this item requested suggestions for additional measures,
and one of the free text suggestions provided (geographical location)
was deemed suitable for reporting. Participants' free text comments
from round 1 can be seen in Section S10. Thirty‐five
definitions/instruments relating to the eight outcomes listed above
were carried forward to the round 2 Delphi questionnaire (Table 4).
3.4.2 | Round 2
The stage 2 round 2 Delphi questionnaire can be seen, as it appeared
to study participants, in Section S11. Within this questionnaire, partic-
ipants were required, for each of the eight included outcomes, to rank
the options provided in terms of their appropriateness for use or to
select a single preferred definition/instrument. As stated, 35
definitions/instruments were carried forward from the stage 2, round
1 questionnaire. However, participants were asked to consider 31
options during the stage 2 questionnaire, the result of baseline and
follow‐up time points being combined where possible, and the addition
of options representing a combination of definitions/instruments for
a given outcome (Section S11).
The 33 expert group members who completed the stage 2, round 1
questionnaire were invited to participate in round 2 and 29/33 com-
pleted questionnaires were received, representing an 88% response
rate (100% of weight management staff, 88.9% of academics, 66.7%
of policy makers, and 50% of commissioners).
As shown in Section S11, participants were asked to rank seven def-
initions for measuring and reporting weight loss at follow‐up in order of
their appropriateness for use. Results are summarised inTable 5. Based
onmean andmedian ratings, all four potential definitions (items 3.1, 3.2,
3.3, and 3.4) were selected to be carried forward to the final
definition/instrument selection Delphi (stage 2, round 3 questionnaire).
Similarly, the expert panel ranked five options pertaining to the
presentation of results at follow‐up in order of their appropriateness
for use (Section S11). Results are shown in Table 6. Based on mean
and median ratings, item 7.5 (combining both items 7.2 and 7.3) was
selected to be carried forward to round 3.
For the remaining six outcomes (completion, participant satisfac-
tion, cost effectiveness, overall measure of comorbidity, depression,
and importance of weight loss), experts were instructed to select the
most appropriate definition/instrument for measurement and
reporting from the options provided (Section S11). Selection fre-
quency for each option was determined, and the option selected most
frequently for a given outcome was then carried forward (Table 7), the
exceptions being “participant satisfaction” and “overall measure of
comorbidity.” For the former, experts' comments and scores indicated
that neither of the suggested instruments (questionnaires) was ideal.
Therefore, it was decided that both instrument options would be
retained for round 3, but the expert panel would be informed that
alternative methods to measure this outcome could be used. In the
case of “overall measure of comorbidity,” the majority of experts indi-
cated that they had insufficient knowledge of the instruments and
were therefore unable to select which would be most appropriate
for use. Consequently, the most frequently selected of the remaining
options, mean Edmonton Obesity Scale Score (EOSS) score, was
selected to be carried forward to round 3.
Participants' free text comments from round 2 can be seen in
Section S12.
3.4.3 | Round 3
Experts were asked to study the final list of selected
definitions/instruments and indicate whether they were in agreement
with the findings of the expert panel. If participants disagreed with the
findings they had the opportunity to express this disagreement and
make suggestions as to any changes they felt should be made. It was
made clear that should a number of experts express similar opinions,
instruments/measurements would be altered appropriately. The stage
2, round 3, questionnaire is included, as it appeared to participants, as
Section S13.
The 29 expert group members who completed the stage 2, round
2, questionnaire were invited to participate in the round 3 Delphi pro-
cess, and 27/29 completed round 3 questionnaires were received,
representing a 93% response rate for this round (100% of weight man-
agement staff, 100% of academics, 50% of policy makers, and 50% of
commissioners). With 27/40 participants completing all three rounds
of the stage 2 Delphi process, the overall response rate for stage 2
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was 67.5% (85% of weight management staff, 72.7% of academics,
25% of policy makers, and 20% of commissioners).
Following analyses of round 3 questionnaires, results revealed that
19/27 experts (70%) approved the results as presented and 8/27
experts (30%) did not. With regard to expert panel subgroups, 7/8
academics (88%) approved the results as presented and 1/8 (13%)
did not. The participant who identified as a commissioner accepted
the results as presented, as did the participant who identified as a pol-
icy maker. Of the weight management staff, 10/17 (59%) agreed with
the results as presented and 7/17 (41%) did not. Therefore, the most
disagreement and, consequently, free text comments came from
weight management staff who tended to pre‐empt their responses
by stating that they partially accepted the results rather than rejecting
them outright (Section S14). Comments suggested that the main con-
cern was related to measures of diabetes status with participants
questioning whether there was capacity in services to perform the
necessary medical tests, who would fund these tests and whether
performing them would place an unreasonable burden on weight
management staff (Section S14). However, with the vast majority of
the expert group in agreement with the results and free text com-
ments of those not in agreement failing to provide a convincing argu-
ment for alteration of the final definition/instrument list, our core and
optional outcome and definition/instrument sets were finalised and
are included as Table 8. As shown, “outcomes” within both sets were
designated as being either process outcomes, outcomes, or guidance
for presentation of results (Table 8).
4 | DISCUSSION
A COS is an agreed minimum set of outcomes for measuring and
reporting for a specific area of health. COSs have been developed
across a range of health areas, including bariatric and metabolic
surgery27. While a recent study obtained expert panel consensus on
recommendations for standard baseline assessment in medical obesity
TABLE 5 Central tendency and spread of ratings for stage 2
(instrument selection), round 2 Delphi items relating to the measuring
and reporting of weight loss at follow‐up
Stage 2,
Round 2
Questionnaire
Item
Definition/
Instrument
Mean
Panel
Rating SD
Median
Panel
Rating IQR
3.1 Mean change in
participants'
weight in kg
4.66 2.22 5 2 to 7
3.2 Mean % weight change
of participants
3.72 1.69 4 3 to 5
3.3 % of participants
achieving ≥5%
weight loss
3.82 1.5 4 3 to 5
3.4 % of participants
achieving ≥10%
weight loss
4.93 1.41 5 4 to 6
3.5 all of the above
measurements
(3.1 + 3.2 +
3.3 + 3.4)
3 2.31 3 1 to 5
3.6 measurements 3.2 +
3.3 (mean % weight
change + %
achieving
≥5% weight loss)
3.55 2.01 3 2 to 6
3.7 measurements 3.3 +
3.4 (% achieving
≥5% weight loss
+ % achieving
≥10% weight loss)
4.31 2.19 4 3 to 7
Note. Participants were asked to rank seven definitions for measuring and
reporting weight loss at follow‐up in order of their appropriateness for use.
Based on mean and median ratings, all 4 potential definitions (items 3.1,
3.2, 3.3, and 3.4) were selected to be carried forward to the final defini-
tion/instrument selection Delphi (stage 2, round 3).
TABLE 6 Central tendency and spread of ratings for stage 2
(instrument selection), round 2 Delphi items relating to the presenta-
tion of results at follow‐up
Stage 2,
Round 2
Questionnaire
Item
Definition/
Instrument
Mean
Panel
Rating
Mean SD
Median
Panel
Rating
Median IQR
7.1 Report outcomes for all
participants
attending ≥1 active
weight loss
session(s) (does not
include introductory
sessions/information
sessions about the
service).
4.1 1.21 5 4 to 5
7.2 Report outcomes for all
participants
attending >1 active
weight loss
session(s) and
therefore having
weight change data
(does not include
introductory
sessions/information
sessions about the
service).
3.26 1.1 3 3 to 4
7.3 Report outcomes for all
participants
completing the
programme.
3.03 1.43 3 2 to 4
7.4 Report 7.1 + 7.3 2.62 1.18 2 2 to 4
7.5 Report 7.2 + 7.3 1.97 1.3 2 1 to 2
Note. Participants were asked to rank five options pertaining to the presen-
tation of results at follow‐up in order of their appropriateness for use.
Based on mean and median ratings, 2 items (items 7.2 and 7.3) were
selected to be carried forward to the final definition/instrument selection
Delphi (stage 2, round 3).
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management clinics28, to our knowledge, the study described herein
is the first of its kind to develop a COS and corresponding
definition/instrument set for BWMIs for adults with overweight and
obesity. This is much needed in order to standardise reporting which,
in turn, will lead to a better evidence base and improvements in weight
management provision. Indeed, within the United Kingdom, PHE
and Health Scotland have agreed to use this work to inform evaluation
plans for adult BWMIs.
A wide range of sources, including the research literature and guide-
line and policy documents, were used to generate lists of potential out-
comes and definitions/instruments. Consensus as to which of these
should be included in the final outcome sets was then determined by a
group of individuals with wide‐ranging expertise in behavioural weight
management. This was achieved by means of the internationally
recognisedDelphi process. Experts includedmembers of the publicwith
experience of BWMIs, academics/commissioners/policy makers work-
ing in weight management, weight management staff and primary care
staff (referrers). There is no published agreement on the optimal size
of an expert group29; pragmatism is required while ensuring a range of
opinions is garnered. For this study, experts were selected according
to our sampling framework to ensure they were representative of the
United Kingdom as a whole, and the online nature of the Delphi process
TABLE 7 Selection frequencies for remaining stage 2 (instrument selection), round 2 Delphi items
Stage 2, Round 2
Questionnaire Item Outcome Definition/Instrument
Selection
Frequency
Selection
Percentage (%)
Retain for
Round 3 Delphi
4.1 Completion % of participants who attended 100% of possible/
core/mandatory sessions
2 7
4.1 Completion % of participants who attended 80% of possible/core/
mandatory sessions
15 52 ✓
4.1 Completion % of participants who attended 70% of possible/core/
mandatory sessions
12 41
5.1 Participant satisfaction Mean OEQ score adapted to suit weight management
services
13 45 ✓a
5.1 Participant satisfaction Mean NHS FFT score 16 55 ✓a
6.1 Cost effectiveness The PHE Weight Management Economic Assessment
Tool
18 62 ✓
6.1 Cost effectiveness Cost/kg (based on mean weight loss) 6 21
6.1 Cost effectiveness Cost per success with success being 5% weight loss 5 17
8.1 Overall measure of
comorbidity
Mean CCI score 2 7
8.1 Overall measure of
comorbidity
Mean EOSS score 7 24 ✓b
8.1 Overall measure of
comorbidity
Mean Chronic Disease Score 3 10
8.1 Overall measure of
comorbidity
Mean number of dispensed medications per participant 1 3
8.1 Overall measure of
comorbidity
I have insufficient knowledge of the instruments and
am therefore unable to select one.
16 55
9.1 Depression Mean HADS questionnaire score of participants 10 34
9.1 Depression Mean PHQ9 questionnaire score of participants 12 41 ✓
9.1 Depression Mean Beck Depression Inventory score of participants 7 24
10.1 Importance of weight loss Mean Dieting Readiness Scale score(s) 15 52 ✓
10.1 Importance of weight loss Mean DIET score(s) 8 28
10.1 Importance of weight loss Mean Self‐Efficacy for Eating Behaviours Scale score(s) 6 21
Note. Participants were instructed to select the most appropriate definition/instrument for measurement and reporting from the options provided for each
outcome. Selection frequency for each option was determined and the option selected most frequently retained for the stage 2, round 3 Delphi.
Abbreviations: SD, standard deviation; IQR, interquartile range; OEQ, Outcomes and Experiences Questionnaire; NHS, National Health Service; FFT,
Friends and Family Test; PHE, Public Health England; CCI, Charlson Comorbidity Index; EOSS, Edmonton Obesity Staging System; HADS, Hospital Anxiety
and Depression Scale; PHQ‐9, Patient Health Questionnaire‐9; DIET, Dieter's Inventory of Eating Temptations.
aParticipants' comments and scores indicated that neither of the suggested instruments was ideal. Therefore, no instrument was selected. These two
options will be given as suggestions but other methods could be used.
bThe majority of participants indicated that they had insufficient knowledge of the instruments and were therefore unable to select which would be most
appropriate for use. Consequently, the most frequently selected of the remaining options, mean EOSS score, was retained for the stage 2, round 3.
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TABLE 8 Core and optional outcome and definition/instrument sets
Core Outcome Set
Process Outcomes
Item Definition Instrument/Measurement/
Presentation to be Used/Reported
(Baseline)
Instrument/Measurement/
Presentation to be Used/Reported
(Follow‐up)
Age How old participants are/the age (in
years) of participants
• Mean age of participants in years
• % of participants in age bands (16‐
24, 25‐34 , 35‐44, 45‐54, 55‐64,
65‐74, 75+ y)
Gendera How participants identify themselves
with regard to being male, female,
or nonbinary/third gender
• % of male, female, or other
participants
Ethnicitya The social group with common
national and cultural tradition that
participants identify as belonging to,
eg, white/white British, Asian/Asian
British, black/African/Caribbean/
black British
• % of participants identifying as
being white, black, Asian, or
Minority Ethnicities
Deprivation categorya A measure of the level of poverty in
the area in which the participant
lives
• Scotland—% of participants in each
Scottish Index of Mass Deprivation
(SIMD) quintile
• England—% of participants in each
English Index of Mass Deprivation
(EIMD) quintile
• Wales—% of participants in each
Welsh Index of Mass Deprivation
(WIMD) quintile
• Northern Ireland—% of participants
in each Northern Ireland Multiple
Deprivation Measure (NIMDM)
decile
Physical disabilitya Whether participants have a
recognised physical disadvantage or
disability
Learning disabilitya Whether participants have a
recognised mental/cognitive
disadvantage or disability
Formally diagnosed with a
mental health conditiona
Whether participants have a current
mental health condition as
diagnosed by a GP or health
professional
• % of participants answering yes
Referral to specialist services
(real world services only)
Whether a participant has been
referred to a specialist management
service (tier 3 or 4) by a GP or tier 2
weight management service after
failing to lose the required amount
of weight via a lifestyle weight
management programme or due to
a condition needing specialist input.
• % of participants
Repeat referrals (real world
evaluations only)
Whether a participant has been
referred to the weight management
service on more than one occasion.
• % of participants previously
referred to the service, not
necessarily having attended any
sessions)
• % of participants answering yes,
having previously attended at least
1 weight management session
(Continues)
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TABLE 8 (Continued)
Core Outcome Set
Attendance How many people attended the
weight management service
• Mean % of core/mandatory
sessions attended by participants
Completion How many people finished the weight
management programme
• % of participants who attended
80% of possible/core/mandatory
sessions
Reason for dropout Why those participants who did not
complete the programme failed to
do so.
% of participants who dropped out
due to:
• Dissatisfaction with the
intervention (unrelated to weight
loss)
• Poor weight loss
• Illness/ hospitalisation
• Pregnancy
• Change in personal circumstances/
social reason
• Moving from the geographical area
• Any other reason
• Unknown reason
Core Outcome Set
Outcomes
Item Definition Instrument/Measurement/
Presentation to be Used/Reported
(Baseline)
Instrument/Measurement/
Presentation to be Used/Reported
(Follow‐up)
Weight The measurement of how heavy a
participant is in kilograms (kg) or
stones and pounds
Mean weight of participants in kg • Mean change in participants'
weight in kg
• Mean % weight change of
participants
• % of participants achieving ≥5%
weight loss
• % of participants achieving ≥10%
weight loss
Body mass index (BMI) An approximate measure of whether a
participant is overweight or
underweight, calculated by dividing
their weight in kilograms by the
square of their height in metres
• Mean BMI of participants
• % of participants in BMI categories
<25, 25‐29.9, 30‐34.9, 35‐39.9,
40‐49.9, 50‐59.9, ≥60
• mean change in participants' BMI
Diabetes status Whether a participant has diabetes, a
condition, which occurs when the
body does not produce enough
insulin to function properly, or the
body's cells do not react to insulin.
This means glucose stays in the
blood and isn't used as fuel for
energy. Type 2 diabetes is often
associated with obesity and an
increased risk of developing
cardiovascular disease.
• % of participants with type 2
diabetes mellitus (based on self‐
report, case record, or blood test)
• Mean change in HbA1c levels of
those participants with T2DM
Quality of life (QoL) score A measure of the general well‐being of
participants.
• Mean EQ‐5D‐5L scores of
participants
• Mean change in EQ‐5D‐5L scores
of participants
Learning disability QoL score A measure of the general well‐being of
participants with a learning
disability.
• Mean Personal Wellbeing Index‐
Intellectual Disability (PWI‐ID)
score(s) of participants
• Mean change in PWI‐ID score(s)
of participants
(Continues)
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TABLE 8 (Continued)
Core Outcome Set
Adverse events/unintended
consequences
Whether participants suffered any
unfortunate side effects as a result
of attending the weight loss service.
Number of participants experiencing
a worsening of a pre‐existing
medical condition, such as
• An undiagnosed eating disorder
• Other pre‐existing medical
conditions
• Number of participants sustaining
an injury during a physical activity
session run by the weight
management service
Participant satisfaction How happy/satisfied participants
were with the weight loss service.
**In this instance, the weight
management service should select
the questionnaire/method they feel
is most appropriate for their use.**
Comments and scores indicate that
neither of the suggested
instruments for measuring patient
satisfaction is ideal. Therefore, it is
proposed that no instrument is
selected. The two options below
will be given as suggestions but
other methods could be used.
• Mean Outcomes and Experiences
Questionnaire (OEQ) score
adapted to suit weight
management services
• Mean NHS Friends and Family Test
(FFT) score
Cost effectiveness The value for money of the weight
management service in terms of
long term economic benefits to the
NHS.
• The Public Health England
Weight Management Economic
Assessment Tool:
• http://webarchive.
nationalarchives.gov.uk/
20170110165804/http://www.
noo.org.uk/visualisation/
economic_asessment_tool
Guidance for Presentation of Results (Core Outcome Set)
Item Definition Presentation to be Used
Presentation of results Which participants' outcomes to
include in reporting
• Report outcomes for all participants attending >1 active weight loss
session(s) and therefore having weight change data (does not include
introductory sessions/information sessions about the service)
• Report outcomes for all participants completing the programme
12‐mo follow‐up Reporting outcomes 12 mo after
starting the weight loss programme
24‐mo follow‐up Reporting outcomes 24 mo after
starting the weight loss programme
Missing data How to deal with participants with
missing weight data (usually
because they have dropped out of
the programme)
• baseline observation carried forward (BOCF) and last observation carried
forward (LOCF) for data at <12 months
BOCF for data at ≥12 months
Optional Outcome Set
Process Outcomes
Item Definition Instrument/Measurement/
Presentation to be Used/Reported
(Baseline)
Instrument/Measurement/
Presentation to be Used/Reported
(Follow‐up)
(Continues)
20 of 25 MACKENZIE ET AL.
TABLE 8 (Continued)
Core Outcome Set
Reach (% eligible population
who are referred to/take up
weight management service)
The percentage of the eligible
population (people who are
overweight or obese within that
particular geographical area)
referred to the weight management
service.
For a specific population subgroup of
concern, what % of that
population has been referred to/
attended the weight management
service. Local data (eg, Quality and
Outcomes Framework) can be
used to obtain prevalence rates.
Population subgroups of interest:
• Age <30
• Male
• People with T2DM
• Other subgroups
Representativeness (how similar
the people attending the
service are to the local eligible
population)
How representative of the entire
eligible population (people with
body mass in the overweight or
obese range within that particular
geographical area) the people
attending the weight management
service are.
• Based on age of participants
• Based on sex of participants
• Based on BMI of participants
• Based on deprivation category of
participants
• Based on ethnicity of participants
• Based on diabetes status of
participants
• Based on the geographical spread
of the home addresses of
participants
Referral to linked services The number of participants referred to
services linked to weight
management services
• % of participants referred to
smoking cessation services,
mental health services, alcohol
services etc
Sources of referral Where participants received their
referral to the weight management
service
• % of participants receiving their
referral from each possible source
dependent on service, eg, from
primary care, from secondary care,
self‐referral, from allied health
professionals, from pharmacy, from
tier 3 weight management services,
from tier 4 weight management
services
Mobility issues Whether participants are unable to
move with ease and without
restriction. Being overweight has
been associated with restricted
mobility.
• % of participants who have
difficulty accessing certain weight
loss service venues and have
impaired ability to exercise
Optional Outcome Set
Outcomes
High blood pressure Whether a participant has high blood
pressure. High blood pressure
increases the risk of developing
cardiovascular disease.
• % of participants with high blood
pressure based on patient report/
medication/case notes
% of participants with high blood
pressure based on blood pressure
readings
Change in % of individuals with
blood pressure above current
recommended treatment
thresholds (ie, normotensive or
adequately treated)
Blood pressure The pressure of blood in the arteries,
the vessels that carry blood from
the heart to the rest of the body. A
certain amount of pressure is
Mean systolic and diastolic blood
pressure of participants
Change in mean systolic and
diastolic blood pressure of
participants
(Continues)
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TABLE 8 (Continued)
Core Outcome Set
required to get the blood around
the body but consistently high
blood pressure increases the risk of
cardiovascular disease.
Cardiovascular risk A measure of how likely participants
are to develop cardiovascular
disease, including heart disease and
stroke
• % of participants with previous
cardiovascular disease (CVD),
including myocardial infarction,
stroke, transient ischaemic attack
(TIA), angina, and peripheral
vascular disease
• % of participants with high CVD
risk (previous CVD or a high
cardiovascular risk score—N.B.
information on blood pressure and
lipids would be required to
calculate the risk score)
• % of participants with a high
cardiovascular risk score (primary
prevention/not those with
previous cardiovascular disease)
mean CVD risk score of
participants (primary prevention/
not those with previous
cardiovascular disease)
• % of participants with a high
cardiovascular risk score (primary
prevention/not those with
previous cardiovascular disease)
• change in mean cardiovascular risk
score of participants (primary
prevention/not those with
previous cardiovascular disease)
High cholesterol/ lipids A measure of whether a participant
has an abnormal amount of fat and/
or cholesterol, known as lipids, in
their blood (also called
dyslipidaemia). Being overweight
can increase the likelihood of
developing dyslipidaemia.
Dyslipidaemia is associated with
increased risk of developing
cardiovascular disease.
• % of participants with high
cholesterol/lipids based on self‐
report /case records
• Mean total cholesterol/ high
density lipoprotein/ triglycerides of
participants as obtained via blood
test
• Mean change in total cholesterol/
high density lipoprotein/
triglycerides of participants as
obtained via blood test
High future risk of diabetes
(impaired fasting glucose,
impaired glucose tolerance,
raised HbA1c levels, previous
gestational diabetes)
Whether measures of the amount of
glucose in a participant's blood
suggests he/she is likely to develop
type 2 diabetes in the future.
• % of participants with a medical
record of high diabetes risk (HDR)
as determined by measuring
HbA1c/fasting glucose/Oral
Glucose Tolerance Test (OGTT)
(either measured during
intervention or in medical records)
• % of all participants with HDR as
determined by measuring HbA1c/
fasting glucose/OGTT (either
measured during intervention or
in medical records)
• % of those participants identified
as having HDR at baseline who still
have HDR (as determined by
measuring HbA1c/fasting glucose/
OGTT) , normoglycemia or type 2
diabetes
Overall measure of comorbidity Measure of the presence of additional
diseases or disorders co‐occurring
with obesity/being overweight
• Mean Edmonton Obesity Staging
System (EOSS) score
• Mean change in EOSS score
Depression Whether a participant suffers from a
mental illness characterised by a
profound and persistent feeling of
sadness or despair and/or a loss of
interest in things that once were
pleasurable.
• % of participants with depression
based on patient report/
medication/case notes
• % of participants on medication for
depression
• Mean Patient Health
Questionnaire‐9 (PHQ‐9) score of
participants
• Change in % of all participants on
medication for depression
• Change in % of those patients
identified as having depression at
baseline on medication for
depression
• Mean change in PHQ‐9
questionnaire score of participants
(Continues)
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ensured that opinions expressed by members of the public were given
equal weighting to those expressed by professionals. However,
throughout the majority of the Delphi process, experts from each of
the four groups were observed to be in agreement as to the importance
of outcomes for reporting from BWMIs and the appropriateness of
definitions/instruments for their measurement. In addition, retention
rates for our experts were high throughout the Delphi process with
82.5% completing stage 1 (outcome selection) and 67.5% completing
stage 2 (instrument selection). These high retention rates can be attrib-
uted to the nature of our recruitment and selection processes. In order
to select a panel based on our sampling framework, potential experts
were asked to provide information on geographical location etc. Those
responding appropriately in a timelymanner demonstrated their willing-
ness to participate and their commitment to the process and were
therefore considered for Delphi expert panel selection. Those failing
to respond to our requests were deemed unlikely to fully engage with
the Delphi process and were not included in the selection process.
Experts agreed on a final core outcome and corresponding
definition/instrument set consisting of 24 items,whichwere designated
as either processes, outcomes, or guidance for presentation of results.
As we may have expected, weight, BMI, attendance, completion, and
cost effectiveness featured in the final COS and follow‐up time points
of 12 and 24 months were stipulated. Experts also agreed that an addi-
tional optional COS was necessary. This included 19 items, again
designated as either processes, outcomes, or guidance for presentation
of results, which BWMIs could report should they wish to do so. Both
the core and optional outcome sets were observed to include outcomes
relevant to patients, clinicians, and commissioners/policy makers,
reflecting the composition of our expert group.
While the vast majority of experts were in agreement with the final
outcome and corresponding definition/instrument sets, some issues
were raised by weight management staff with regard to the feasibility
of the outcomes. With these concerns in mind, it should be noted that
the measurement of each outcome is not considered mandatory for
every patient/participant; the outcome sets are merely intended to
serve as a guide for planned evaluations. A lack of funding and
requirement for evaluation is a key issue for real‐world services. The
majority of outcomes in the COS are generally measured during rou-
tine care, but it is recognised that certain outcomes will prove more
challenging for weight management staff, an example being the deter-
mination of haemoglobin A1c (HbA1c) levels if linking to routinely
measured test results is not possible. In addition, information on lon-
ger term outcomes (at 12 and 24 months) is likely to be difficult to
obtain given the relatively short duration of the majority of BWMIs.
Furthermore, those participants who regain weight are less likely to
provide weight details or return to be weighed at a later stage. As
such, research is needed in order to improve linkage to health records
and to determine how best to persuade patients/participants to
TABLE 8 (Continued)
Core Outcome Set
Self‐confidence and self‐esteem How participants feel about their own
abilities and worth
• Mean Warwick‐Edinburgh Mental
Well‐being Scale (WEMWBS) score
• Mean change in WEMWBS score
Importance of weight loss How important participants feel it is
for them to lose weight
• Mean Dieting Readiness Scale
score(s)
Disordered eating Whether participants have disturbed
and unhealthy eating patterns that
can include restrictive dieting,
compulsive eating or skipping
meals. Disordered eating can
include behaviours, which reflect
many but not all of the symptoms of
feeding and eating disorders such as
anorexia nervosa, bulimia nervosa,
and binge eating disorder.
• % of participants with disordered
eating (defined as per service)
• Change in % of participants with
disordered eating (defined as per
service)
Prescription of anti‐obesity
medication
The number of participants taking
drugs to help reduce or control their
weight
• % of participants on any anti‐
obesity medication (total and by
class/medication)
• Change in % of participants on
anti‐obesity medication (total and
by class/medication)
Guidance For Presentation of Results (Optional Outcome Set)
3‐mo follow‐up Reporting outcomes 3 mo after starting the weight loss programme
6‐mo follow‐up Reporting outcomes 6 mo after starting of the weight loss programme
18‐mo follow‐up Reporting outcomes 18 mo after starting the weight loss programme
Note. The expert group agreed on a final core outcome and corresponding definition/instrument set consisting of 24 items. Twelve of these items were
designated as processes, eight were designated as outcomes, and four were designated as guidance for presentation of results. Experts agreed on an
optional outcome set consisting of 19 items; five processes, 11 outcomes, and three items relating to presentation of results.
aThese items are considered “protected characteristics” and therefore, in keeping with government guidelines, have been included in our core outcome set.
These items are more relevant for real world services which are required to report such items to higher authorities. As such, these items are only core or
mandatory for reporting when required in real life.
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engage with longer term outcomes1, perhaps by digital means, such as
blue tooth scales or mobile apps. There is also a need for commis-
sioners to consider the benefits of evaluation at the point of commis-
sioning a service and ensuring that the service is funded sufficiently in
order to gain meaningful insights30.
This study was, of course, restricted to the United Kingdom. This is
due to BWMIs and their settings within health services being fairly
country‐specific. For example, in France and the Netherlands, there
is no health insurance funding of BWMIs, and in the United States
of America (USA), obesity services are tertiary, combining behavioural
programmes with medication and bariatric surgery. Instruments can
also be country‐specific due to differences in language and health eco-
nomic models, for example. In addition, “international” studies are
often tokenistic, including only a small percentage of participants from
outside the country in which the study is set. Within the “interna-
tional” BARIACT study for example, the vast majority of professionals
(95.2%) and patients (95.6%) participating were from the United King-
dom27. Our preference was to develop a COS with a balanced stake-
holder group using a sampling framework to ensure wide
representation; to do this on a truly international scale would be
impossible. Consequently, if used in an international context for trials
or real world services, our core outcome and definition/instrument set
may require further adaptation. Therefore, the next step may be to
undertake international validation of the COS. This could involve con-
sensus meetings with professionals and patients in other countries.
In conclusion, this study has used internationally recognised meth-
odology to develop a COS for BWMIs. Its widespread adoption by
both clinical trialists and weight management programmes will
improve the quality of data from research studies and real‐life ser-
vices, thus improving the evidence base and weight management
provision.
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